Zr-TCO-LNP) to be immobilized on the tetrazine surface to the control suspensionso fn on-TCO functionalized 89 Zr-liposomaln anoparticles.U ltimately,t his platform technology could result in as ystemic decrease of the radiotherapeutic dose deposited in non-targetedt issues by specific removalo flong-circulating liposomal radiopharmaceuticals from the blood pool.
Liposomal radiopharmaceuticals have drawn much attention as clinicald iagnostics and/or therapeutics in recent years. [1] [2] [3] [4] [5] They have been employeda sl ow excretion blood-pool imaging agents, labeled with 18 F, [2] as nanoreporters to predict therapeutic outcome during Doxil treatment, [3] anda sb one marrow imaging agents, tagged with 64 Cu. [5] Nanoparticles that are not decorated with am olecularly targeted small molecule, peptide, or antibody can still passively accumulate in tumors, exploiting the enhanced permeability and retention (EPR) effect. [6] This increaseda ccumulationo ft he liposomal radiopharmaceutical in tumor regionsa llows delineation of tumor margins with positrone mission tomography (PET), generallya t late time points between 24 and4 8h.H owever, long-circulating liposomal radiopharmaceuticalst agged with long-lived radionuclides such as 89 
Zr and 64
Cu can deposit as ignificant dose of radiation to non-targeted organs, such as the liver and spleeno fp atients. [7] Thus, it would be beneficial to utilize early time-point imaging (ideally between 4-6 hp ost-injection) of long-circulating liposomal nanoparticles so that sufficient tumor signal-to-background ratios can be realized withoutu nnecessary circulation of potentially deleterious radioisotope nanocarriers. We, therefore, designed al iposome-based tetrazine (Tz)/trans-cyclooctene (TCO) targeting system by using the inverse electrondemand Diels-Alder (IEDDA)c lick reaction (Figure1). Over the last six years, the potentialo ft his reactionh as been exploited as at ool for the in vitro and in vivo labeling of biologically relevant probes. [8] This extremely fast (k > 30 000 m À1 s
À1
), selective, andb ioorthogonalc lick reaction [9] has been successfully introduced as ap retargeting system for in vivo PET imaging [10] as well as aradioimmunotherapeutic.
[11] Figure 1 . Schematic overviewo f 89 Zr-TCO-liposomeu ptake via bioorthogonal inverse electron-demand Diels-Alder click reaction.
[a] Dr.C . Brand In this Communication,w ep resent our recent results towards the development of aplatform technology for in vivo removal of al iposomal radiopharmaceutical through the IEDDA reaction. Bioorthogonally reactive liposomes can potentially result in as ystemic decrease of the radiotherapeutic dose depositedi nh ealthy tissues, yield al arger therapeutic window, better treatment outcomes, and ultimately more satisfactory prognoses.
To this end, we synthesized 89 Zr-radiolabeled TCO-functionalized liposomes (Figure 2 ). The preparation of TCO-functionalized liposomaln anoparticles required the synthesis of ad erivative of the phospholipid1 ,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE-NH 2 ,F igure S1). DSPE-NH 2 was treated with aT CO-functionalized N-hydroxysuccinimide (TCO-NHS) ester in the presence of triethylamine to obtain the desired TCO-functionalized phospholipidi nm oderate yields. After purification, DSPE-TCO was characterized by using mass spectrometry with electrospray ionization (ESI-MS) ( Figure S1B ). The TCO-functionalized liposomal nanoparticles can then be assembled by using ap reviously established protocol. [4] To gether with 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), cholesterol, DSPE-PEG2000, DSPE-TCO, and DSPE-desferrioxamine (DSPE-DFO), a high-pressure tip-sonication method yielded the TCO-functionalized liposomal nanoparticle( TCO-LNP) suspensiono fn arrow size distributions (meand iameter = 109.4 AE 8.8 nm, PDI = 0.153 AE 0.027). The overall charge of TCO-LNP was measured to be slightly negative, with az eta potential of À6.8 AE 4.4 mV. Subsequentr adiolabeling of the TCO-LNP surface chelate moieties was achieved throught reatment with radioactive 89 Zr(IV)-oxalate ( Figure 2A) . The desired 89 Zr-radiolabeled TCO-functionalized liposome ( 89 Zr-TCO-LNP) wasi solated by centrifugal filtration in good radiochemicaly ield (49 AE 5%). Size exclusion chromatography (SEC) exhibited high radiochemical purity (> 97 %) of the radiolabeled, or "hot", liposome population ( Figure 2B )w ith no statistically significant difference in particle size and distributions comparedt oi ts "cold" precursor (Figure 2C ). Biodistribution studies in 4T1-tumor-bearing nude mice showed typical pharmacokineticso fP EGylated liposomal nanoparticles with increasingr atios of tumor to blood over 24 ho fu pt o3 .12 AE 0.57 ( Figure 2D and Figure S2 ). It is important to note that while tumor/blood ratios increase between 6 and 24 h, sufficient tumoral uptake of 89 Zr-TCO-LNPs was observed as early as the 6htime point. In fact, the mean percent injectedd ose per gram (%ID g À1 )o ft umoral tissue actually decreasesb etween 6a nd 24 h( 17.0 AE 4.2 and 14.0 AE 1.2 %ID g À1 for 6a nd 24 h, respectively). Enhanced contrasts hould not only be achieved by increased particle accumulation, but ratherc learance of 89 Zr-TCO-LNPsf rom the blood pool. Ar apid route for selectivet racer removal from the blood pool would, therefore, decrease the radiation dose as wella sa llow for earlier imaging time points.
Rationally,atetrazine-functionalized polydopamine-coated CoCrMo stent alloy was prepared so that bioorthogonally selectiver emovalo f 89 Zr-TCO-LNPs can be realized (Figure3). The inherentc hemical robustness of these particular alloys allows them to be suitable as core materials for frameworkinga rterial stents. The noble metal surfacec haracter of thesea lloys also suggestst hat at horough oxidation treatment can allow for a subsequentt reatment with af unctionalized organic substrate through the resulting strong Vand er Waals forces and covalent interactions between the substrate and the metal.R ecent preparations of polydopamine (PDA)-coated CoCr alloys utilized such strategies to install functional amineso nt he metal surfacep rimarily through the chelating catechol moieties of the dopamine monomer. [12] These functional handles were ultimately employed as linkers to slow-releasing crosslinkedc yclodextrinsf or drug delivery,a lthough PDA and its polymerica nalogues can be utilized in many other applications. [13] In this report, aP DA-coated CoCrMo alloy wasp repared by peroxidemediated surface oxidation, rendering the metal surface reactive to the catechol groups on dopamine molecules (Figure 3A) . Subsequentt hermalt reatment cured the surfacec oating through polymerization of the adjacently grafted dopamine molecules. It should be noted that the microstructure of polydopamine can vary from monomer to monomer unit, where quinone, indole, and quinhydrone-derived moieties may exist, although their favorable intermolecular interactions contribute to not only the robustness of the bio-inspired resin, [14] but can even contributet oe nhanced hemocompatibility. [15] Figure 2. Synthesis,chemical characterization,a nd in vivo biodistribution of 89 Zr-labeled TCO-functionalized liposomalnanoparticles. a) Formulation and radiolabeling. b) UV (254 nm) andradio-chromatogram by size exclusion chromatography.c)Analysis of size and polydispersity of 89 Zr-labeled liposomal nanoparticle. d) In vivo biodistribution of 89 Zr-TCO liposomaln anoparticles in 4T1-tumor-bearingnude mice. The grafted amines werec onverted in the second step to tetrazine-appended amides by using N-hydroxysuccinimide-displacementc hemistry.T he amide-bound tetrazines can selectively "click" with trans-cyclooctene groups on substrates such as liposomes (Figure 3B ), immobilizing the macromolecular carriers and potentially removing them from circulation. Different concentrationso fT z-NHS ester solutions (0.2 mm,2 .0 mm, and 20 mm)w ere evaluated fort he functionalization of PDA@-CoCrMo-alloy disks to achieve maximum deposition of Tz functionalitieso nt he polydopamine-coated metal surface. After tetrazinef unctionalization, Tz-PDA@CoCrMo disks( n = 3) were incubated with 89 Zr-TCO-liposomes at room temperature for 5min and the bound activity was measured through g-counting. In all cases, we observed as tatisticallys ignificant increase in uptake of 89 Zr-TCO-liposomal nanoparticles on the Tz-functionalized CoCrMo alloy disks (Tz-PDA@CoCrMo) in comparison to PDA@CrCoMo metal disks, demonstrating the successful deposition of tetrazine functionalitieso nt he polydopaminecoated metal disks. However,n os tatistical difference between the different concentrationsofTz-NHS ester was observed.
The viability of ac onceptual liposome" filter" that could be suitable as as tent material was evaluated through radiolabeling efficiencies of CoCrMo alloy disks of variousc oatings (Figure 4) . The tetrazine-appended polydopamine-coated CoCrMo surface( Tz-PDA@CoCrMo) was treatedw ith ab uffered radiolabeled TCO-functionalized liposome formulation as well as non-TCO functionalized 89 Zr-labeledl iposomes (Figure4A), and was left to stand for 5min prior to arinsetoremove residual "unbound" liposomes ( Figure 4B ). The amount of radioactivity retained was compared to ab are CoCrMo alloy and a non-tetrazine-functionalized PDA@CoCrMo, both of which were treated with the same radiolabeled liposomes olutions. Figure 4C depictsp hosphor autoradiography films displaying the radioactivity that had remained on the disk surfaces. Four times less radioactivity was retained on the bare CoCrMo alloy compared to the Tz-functionalized disks with the highesta ctivity,s uggesting that the TCO-tetrazine click reaction is responsible for the enhanced uptake of the liposomes.A lthough considerably more radioactivityw as retained on the tetrazine-functionalized PDA@CoCrMo disk, at wo-fold decrease in the amount was still observed on the disk that was not treated with Tz NHS-ester.T his could be because of side reactions of the strained Z-isomer of the cyclooctene, whichc an include Michael addition to the polydopamine amine or even DielsAlder couplings with catechol-derived quinone dienes. [14] Owingt ot he bioorthogonal click reaction, the majority of PDA-liposome binding originates from the positivelyc harged polydopamine surface itself, which may have an inherent electrostatic affinity for the negatively chargedliposomes. 89 Zr-TCO-liposomal nanoparticles versus 89 Zr-liposomal nanoparticleso nC oCrMoa lloy stent surfaces. a) Synthesis of TCO-functionalized and non-TCO-functionalized 89 Zr-labeledl iposomal nanoparticles.b )Schematicillustration of the experimental setup.c ,d)Analysis of bound activity of 89 Zr-labeled nanoparticlesb yphosphor autoradiography. In summary, 89 Zr-radiolabeled TCO-functionalized liposomal nanoparticles ( 89 Zr-TCO-LNP) with good in vivo pharmacokinetics were prepared for selectiveb inding to ar ationally engineered tetrazine-appendedp olydopamine-coated CoCrMo alloy disk. We have showns pecific binding between theset wo counterparts through the rapid bioorthogonal inverse electron-demand Diels-Alder click reaction between tetrazinesa nd trans-cyclooctenes. This report represents the first steps taken towardsanew technology of on-demand removal of circulating liposomal nanoparticles in vivo.
Experimental Section Materials
Unless otherwise stated, all chemicals and solvents were used without further purification. Water used for this study was ultrapure (> 18.2 MW cm À1 at 25 8C), and acetonitrile (CH 3 CN) as well as ethanol were of HPLC grade purity. l-Dopamine hydrochloride, Trizma base, p-benzylamino tetrazine N-hydroxysuccinimidyl ester (Tz NHS ester), triethylamine, and dimethylformamide were purchased from Sigma-Aldrich (USA) and used as received. Phospholipids were purchased from Avanti polar Lipids. Cobalt chromium molybdenum alloy disks (CoCrMo, 63:30:7 wt %) were purchased from American Elements (CA, USA). TCO-NHS ester was purchased from KeraFast (MA, USA). Chelexed water was prepared with BT Chelex 100 Resin (Bio-Rad) and phosphate-buffered saline (PBS) was purchased from the media preparation facility at Memorial Sloan Kettering Cancer Center. 89 Zr-oxalate was purchased from the radiochemistry core at Memorial Sloan Kettering Cancer Center.H PLC reactions and quality controls (1.0 mL min
À1
,p hosphate-buffered saline) were performed on aS himadzu UFLC HPLC system equipped with aD GU-20A degasser,aSPD-M20A UV detector,a LC-20AB pump system, aC BM-20A communication BUS module, and aS can-RAM radio-TLC/HPLC-detector form Lablogic using a size exclusion column (GE Superdex TM 200, 10/300 GL). Electrospray ionization mass spectrometry (ESI-MS) spectra were recorded with aW aters Acquity UPLC (Milford, CA) with electrospray ionization SQ detector.S ize and zeta potential measurements were performed on aMalvern Zetasizer NanoSeries.
Formulation of TCO-Functionalized Liposomal Nanoparticles
The formulation of TCO-functionalized liposomal nanoparticles is based on ap reviously established protocol. [4] In detail, the liposomal nanoparticle suspension consisting of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), cholesterol, pegylated DSPE (DSPE-PEG2000), DSPE-TCO, and DSPE-DFO in a1 .85:1:0.15:0.03:0.01 molar ratio was prepared by adding the individual lipids to ar eaction vessel in as olution of chloroform. After removing the organic solvent under reduced pressure, the resulting lipid film was dried under high vacuum for 2h.P hosphate-buffered saline (pH 7.4, 4.0 mL) was added to the reaction vessel and stirred at 40 8Cf or 1h.F ollowed by tip sonication and centrifugation, TCO-functionalized liposomal nanoparticles were isolated and stored as as uspension in PBS. Particle diameters were measured to be 109.4 AE 8.8 nm (n = 3) with ap olydispersity index [PDI] of 0.153 AE 0.027 (n = 3) and az eta potential of À6.8 AE 4.4 mV (n = 3). Non-functionalized liposomal nanoparticle suspensions without the DSPE-TCO constituent were prepared as control formulations and exhibited analogous properties to those reported by Perez et al. [4] Radiolabeling of 89 Zr-TCO-Liposomes 89 Zr-oxalate (7.3 mL, 98 mCi)w as added to phosphate-buffered saline (100 mL) and the pH was adjusted to 7.5 by additing Na 2 CO 3 (1 m,7 .0 mL). After the addition of as olution of TCO-liposomal nanoparticles (100 mL), the reaction mixture was incubated at 40 8C for 1h.A fter purification by sequential spin filtration (5 )u sing Amicon filters (100 kDa, EMD Millipore), 89 Zr-TCO-liposomal nanoparticles were isolated (49 AE 5% radiochemical yield, > 97 %r adiochemical purity, n = 5) with similar characteristics (size:1 03.5 AE 5.4 nm and PDI:0 .114 AE 0.071, n = 3) as their precursors.
Biodistribution of 89 Zr-TCO-Liposomes
Evaluating the in vivo performance of 89 Zr-TCO-liposomes, 4T1-tumor-bearing (150-200 mm 3 )m ice (female, nude, 6-8 weeks, 20-25 g) were intravenously injected with as olution of 89 Zr-TCO-liposomes (13.3-18.2 mCi, 0.5 mmol of lipid) in PBS (150 mL). At predetermined time points (2, 6 , and 24 hp ost-injection), the mice were euthanized by asphyxiation with CO 2 and blood was collected via cardiac puncture. Selected organs were harvested, weighed, and counted by using aW izard 2 
Preparation of Tetrazine-Functionalized Stent Alloy
Functionalization of commercial CoCrMo alloy disks was achieved by coating the surface with ap olydopamine coating using am odified literature protocol. [12] Amidization of surface amines through N-hydroxysuccinimide (NHS) displacement yields tetrazine covalencies. The alloy disk was first surface-treated with piranha solution (3:1 w/w H 2 SO 4 8.5 ) and agitated at 20 8Cf or 16 h. After rinsing with water,t he disks were cured at 150 8Cf or 1h.T he resulting polydopaminecoated disks (PDA@CoCrMo) were then incubated in the dark at 20 8Cw ith layer of pipette-dropped solutions of Tz NHS ester (0.2 mm,2 .0 mm,o r2 0mm)a nd triethylamine (0.15 mm)f or 1h prior to aw ater rinse to afford the tetrazine-appended surfacecoated alloy (Tz-PDA@CoCrMo). Then, the reaction solution was removed by washing with water (3 1.0 mL).
Optimization of Tetrazine Functionalization of Polydopamine-Coated CoCrMo Alloy Disks
After the dilution of 89 Zr-TCO-liposomal nanoparticles (100 mL, 62 mCi)w ith PBS (1.0 mL), Tz-PDA@CoCrMo disks prepared under various Tz NHS ester conditions (0.2 mm,2 .0 mm,a nd 20 mm; n = 3) and non-functionalized PDA@CoCrMo disks (n = 3) were incubated with as olution of 89 Zr-TCO-liposomal nanoparticles (100 mL) for 5min at 20 8C. The disks were then carefully washed with PBS (10 mL) and residual radioactivity on the disks was measured by using aWizard 2 automatic g-counter from PerkinElmer. 
